Skip to main content

NCBiotech News

  • A cell-based therapy developed in Durham for a rare liver disease in newborns has been accepted for regulatory review in Canada.
  • Raleigh-based Innovate Biopharmaceuticals may become a publicly traded company soon following an agreement to merge with a California company already listed on the NASDAQ stock exchange.
  • NCEast Alliance, a Greenville-based economic development organization serving 28 counties with about 1.3 million residents in eastern North Carolina, will receive $100,000 from the state to help develop the region’s growing life science sector.
  • Panaceutics, a personalized medicine and clinical nutrition company in Research Triangle Park, will partner with Florida Hospital’s Cardiovascular Institute on a new way to help patients with heart disease take all of their medicines as prescribed. Panaceutics, a personalized medicine and clinical nutrition company in Research Triangle Park, will partner with Florida Hospital’s Cardiovascular Institute (CVI) on a new way to help patients with heart disease take all of their medicines as prescribed.
  • First Flight Venture Center has set a date of September 13, 2017 to roll back the doors of Hangar6, calling it “an advanced rapid prototyping facility.”
  • The billion-dollar cell culture Seqirus vaccine factory in Holly Springs has hit yet another milestone. The highly skilled workers at the sprawling factory southeast of Raleigh successfully produced the world’s first cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.
  • Durham-based Innocrin Pharmaceuticals, a clinical-stage company focused on developing new cancer treatments, has received a regulatory boost for its work in Europe.
  • CiVentiChem has received its first U.S. Food and Drug Administration approval for a generic commercial active pharmaceutical ingredient (API) manufactured at its Cary headquarters.
  • Eat colorful meals and make sure you get enough choline. That’s the key advice two nutrition experts offered during lunch at the Medical, BioMedical & BioDefense: Support the Warfighter symposium in Chapel Hill last week.
  • This post will be updated with news, stories and observations from the Biotechnology Innovation Organization's 2017 conference in San Diego, June 19-22.
  • Humacyte, a Morrisville-based regenerative medicine company, has been selected as one of the World Economic Forum’s 30 “Technology Pioneers” for 2017.
  • The U.S. Special Operations Forces, which include Navy Seals, Army Rangers, and Air Force Special Tactics, have 9,500 people deployed in 90 countries. So they have special needs when it comes to acquisitions from private-sector partners.
  • Achelios Therapeutics of Chapel Hill has completed a meeting with the U.S. Food and Drug Administration about a path to approval for its leading drug candidate, TOPOFEN, to treat acute and chronic migraine, a condition known for its debilitating pain.
  • Covance Drug Development, a global contract research organization that was acquired by Burlington-based LabCorp two years ago, has opened a new companion diagnostics laboratory in Morrisville to extend its capabilities in precision medicine.
  • One thing was clear, from the opening keynote to the final session, after a unique gathering of North Carolina business and Pentagon procurement leaders: the military is actively seeking private-sector partners to support the health and healing of U.S. warfighters and their families.
  • A Virginia man has become the first person in the world to be treated for pancreatic cancer with a bio-absorbable, implantable radiation device called CivaSheet, developed by Durham-based CivaTech Oncology.  
  • Merz Neurosciences, a division of Raleigh-based Merz North America, has reported positive results from a Phase 3 clinical trial of its drug Xeomin for the treatment of adult sialorrhea, or unwanted drooling, due to Parkinson’s disease and other neurologic disorders.
  • In a big win for its surgical business, Durham-based Bioventus says all of its surgical orthobiologics products are now available through Premier Inc., a large group purchasing organization consisting of 3,750 U.S. hospitals and more than 130,000 other healthcare providers.
  • Appalachian State University’s Human Performance Laboratory on the N.C. Research Campus (NCRC) is recruiting at least 30 more male and female walkers and runners this month to determine if a 45-minute walk has the same effect on the digestion and circulation of healthful flavonoids as a 2.5-hour run.
  • Chiltern, a global contract research organization (CRO) with U.S. headquarters in Wilmington, has acquired Integrated Development Associates Co. Ltd. (IDA), a Japanese CRO that specializes in integrating Japan and Asia into global drug development.


Subscribe to News & Events